Bavarian Nordic ( OTCPK:BVNKF ) ( OTCPK:BVNRY ) is exploring the possibility of outsourcing some of the manufacturing, including technology transfer, of its monekypox vaccine to a contract manufacturer in the U.S. as demand surpasses the supply of the only approved vaccine for the virus, Bloomberg News reported .
Rolf Sass Sorensen, vice president at the Danish company, told Bloomberg that Bavarian was no longer certain that it could continue to meet the demand it was facing despite the upgrade of its existing manufacturing facility in Denmark.
"We are also investigating a tech transfer to a contract manufacturer in the US to increase capacity," added Sorensen.
Bavarian President and CEO Paul Chaplin earlier in August said that a potential technology transfer for the monkey pox vaccine Jynneos to a U.S.-based producer could take nearly three months if the process was sped up, compared to about nine months under usual circumstances, the report added citing a Danish news outlet Borsen .
In July, the company said it was in talks with contract manufacturers and other vaccine makers to potentially expand the manufacturing output of Jynneos.
As of Aug. 16, there were 12,689 total confirmed monkeypox/orthopoxvirus cases in the U.S., as per the U.S. CDC.
The company's vaccine MVA-BN is sold as Imvanex in Europe, as Jynneos in the U.S., and under the name Imvamune in Canada and is approved for use against monkeypox and smallpox in the U.S. Canada and the EU.
For further details see:
Bavarian Nordic mulls outsourcing monkeypox vaccine manufacturing as demand outstrips supply - Bloomberg